In RCC-bearing mice injected with a hydrogel mixed with IFN-α combined with sorafenib oral administration, angiogenesis was inhibited, apoptotic cells increased, and tumor proliferation was inhibited. This evidence concerns the gene IFNA1 and renal cell carcinoma.